Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Update November 2021

Wolf, S. (2021): Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Update November 2021. Oncology Fact Sheet Nr. 58.

[thumbnail of Oncology Fact Sheet Nr.58_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
104kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 58
Deposited on:	19 Jul 2021 10:55
Last Modified:	15 Nov 2021 14:51

Repository Staff Only: item control page